Objective  To investigating the usage and changing trend of new anti-tumor drugs for respiratory system of 121 hospitals after the implementation of relevant policies insurance negotiation in China from 2019 to 2022, explore the development tendency of new anti-tumor drugs in hospitals under the medical reform policy and provide references for the rational use and standardized management of new anti-tumor drugs.

Methods  Based on the anti-tumour drug for respiratory system varieties in the Guidelines for the Clinical Application of Novel Anti-tumour Drugs Version 2022, descriptive statistical analysis was applied to retrieve data on the use of new anti-tumour drugs for respiratory system in 121 hospitals from 2019 to 2022, and drug dosage form, amount, drug frequency (DDDs), average daily cost (DDC) and drug ranking ratio (B/A) were statistically analyzed.

Results  The number of users and the proportion of new anti-tumour drugs for respiratory system used in 121 hospitals in China showed a year-on-year increasing trend from 2019 to 2022. In different cities of China, the drug use amount of Guangzhou, Beijing, Hangzhou and Zhengzhou was relatively large. In terms of drug use, small-molecule targeted drugs were still the main new anti-tumor drugs, while macromolecule targeted drugs showed a downward trend, and immunotherapy drugs showed a gradual upward trend. In terms of the amount of use, the top drugs in the four years were ecitinib, aletinib, gefitinib and oxitinib. The small molecule targeted drugs included in the national insurance negotiations showed increasing use and a decreasing amount of money spent. The ranking of DDDs was basically stable, with fluctuations in individual varieties. The DDC values of small molecule targeted drugs had significantly decreased, while the DDC values of immunotherapy drugs were relatively high. From 2021 to 2022, the B/A value of the novel anti-tumor drugs was most respiratory tumors was close to 1, and the varieties located at 0.8 to 1.2 accounted for 61.5% of the total drugs.

Conclusion  At present, the selection of new anti-tumor drugs for respiratory system is still dominated by small molecule targeted drugs and the use of immunotherapy drugs is increasing. The synchronization of the amount and frequency of most drugs has increased. The adjustment of the medical insurance catalog and the implementation of policies such as national negotiation effectively promote the decrease of the amount of drug use and the improvement of drug trend.

1.Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035.

2.周颖玉, 徐冬艳, 齐云, 等. 中国医院抗肿瘤药物使用情况分析[J]. 中国医院药学杂志, 2021, 41(18): 1817-1822. [Zhou YY, Xu DY, Qi Y, et al. Prescription status of antitutor drugs at Chinese hospitals[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(18):1817-1822.] DOI: 10.13286/j.1001-5213.2021.18.01.

3.李凯悦, 刘辉, 蒋倩. 历年国家医保谈判药品概况与分析——抗肿瘤药品专题[J]. 肿瘤药学, 2021, 11(2): 229-235. [Li KY, Liu H, Jiang Q. Overview and analysis on the National Medical Insurance negotiation drugs over the years: taking anti-cancer drugs as an example[J]. Anti-tumor Pharmacy, 2021, 11(2): 229-235.] DOI: 10.3969/j.issn.2095-1264.2021.02.20.

4.蒋慧群, 李歆, 韩峰. 国家医保谈判抗肿瘤药物在常州地区可获得性和可负担性研究[J]. 中国药物警戒, 2021, 18(11): 1075-1079. [Jiang HQ, Li X, Han F. Availability and affordability of national medical insurance negotiated innovative anticancer drugs in Changzhou[J]. China Academic Journal, 2021, 18(11): 1075-1079.] DOI: 10.19803/j.1672-8629.2021.11.17.

5.郭玉娇, 罗璨, 邹颖. 2015—2019年南京地区37家医院新型口服抗肿瘤药物利用分析[J]. 药物流行病学杂志, 2021, 30(10): 687-694. [Guo YJ, Luo C, Zou Y. Investigation of clinical application of new oral antitumor drugs used in 37 hospitals in Nanjing during 2015-2019[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(10): 687-694.] DOI: 10.19960/j.cnki.issn1005-0698.2021.10.009.

6.中华人民共和国国家卫生健康委员会. 呼吸系统肿瘤用药的临床应用—2022版新型抗肿瘤药物临床应用指导原则[J]. 中国合理用药探索, 2023, 20 (4): 16-36. [National Health Commission of the People's Republic of China. Clinical application of respiratory cancer drugs: guidelines for clinical application of novel antitumor drugs (2022 edition)[J]. Chinese Journal of Rational Drug Use, 2023, 20(4): 16-36.] DOI: 10.3969/j.issn.2096-3327.2023.04.004.

7.刘跃华, 向贵圆, 刘昭. 我国抗肿瘤靶向药物医保政策实施现状与改进建议[J]. 中国药物经济学, 2022, 17(9): 57-60, 66. [Liu YH, Xiang GY, Liu Z. Implementation status and improvement suggestions of medical insurance policies for anti-tumor targeted drugs[J]. China Journal of Pharmaceutical Economics, 2022, 17(9): 57-60, 66.] DOI: 10.12010/j.issn.1673-5846.2022. 09.010.

8.陈红斗, 李伟, 陆伟, 等. 2020—2021年我国国家医保谈判抗肿瘤药物的可及性及应用分析[J]. 中国医院药学杂志, 2023, 43(5): 530-535. [Chen HD, Li W, Lu W, et al. Analysis of the availability and utilization of national negotiation anticancer drugs in China from 2020 to 2021[J]. Chinese Journal of Hospital Pharmacy, 2023, 43(5): 530- 535.] DOI: 10.13286/j.1001-5213.2023.05.11.

9.徐佳兰. 2020年—2022年某院国家医保谈判抗肿瘤药物的可及性及应用分析[J]. 中国医药指南, 2024, 22(6): 82-84, 88. [Xu JL. Analysis of the availability and utilization of antineoplastic drugs passing national medical insurance negotiation in the hospital during 2020-2022[J]. Guide of China Medicine, 2024, 22(6): 82-84, 88.] DOI: 10.15912/j.issn.1671-8194.2024.06.025.

10.王秋桐, 赵瑞, 刘颖, 等. 奥希替尼治疗晚期非小细胞肺癌的临床研究进展[J]. 中国新药与临床杂志, 2023, 42(3): 159-165. [Wang QT, Zhao R, Liu Y, et al.Clinical research progress of osimertinib in treatment of advanced non-small cell lung cancer[J]. Chinese Journal of New Drugs and Clinical Remedies, 2023, 42(3): 159-165.] DOI: 10.14109/j.cnki.xyylc.2023.03.03.

11.Cheng Y, He Y, Li W, et al. Osimertinib versus comparator EGFR-TKI as first-line treatment for EGFR- mutated advanced NSCLC: FLAURA China, a randomized study[J]. Target Oncol, 2021, 16(2): 165-176. DOI: 10.1007/s11523-021-00794-6.

12.邢如月, 李梦梦, 张国伟, 等. 阿美替尼治疗EGFR突变晚期非小细胞肺癌疗效及安全性分析[J]. 肿瘤学杂志, 2022, 28(6): 472-478. [Xing RY, Li MM, Zhang GW, et al. Efficacy and safety of almonertinib for patients with EGFR-mutant non-small cell lung cancer[J]. Journal of Chinese Oncology, 2022, 28(6): 472-478.] DOI: 10.11735/j.issn.1671-170X.2022.06.B006.

13.Lu S, Dong X, Jian H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations[J]. J Clin Oncol, 2022, 40(27): 3162-3171. DOI: 10.1200/JCO.21.02641.

14.夏铮铮, 梁小冰, 李超, 等. 基于真实世界的安罗替尼临床应用及安全性分析[J]. 药物流行病学杂志, 2019, 28(7): 444-446. [Xia ZZ, Liang XB, Li C. Investigation on the use and safety of anlotinib based on real world study[J]. Chinese Journal of Pharmacoepidemiology, 2019, 28(7): 444-446.] DOI: 10.19960/j.cnki.issn1005-0698.2019.07.006.

15.Wang Y, Shen S, Hu P, et al. Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs aſter crizotinib failure: real-world evidence[J]. Cancer Med, 2022, 11(23): 4491-4500. DOI: 10.1002/cam4.4834.

16.陈春枚, 林文宏, 赵志斌, 等. 国家医保谈判抗肿瘤药物使用动态分析[J]. 海峡药学, 2023, 35(4): 62-66. [Chen CM, Lin WH, Zhao ZB, et al. Dynamic analysis of antineoplastic drugs passing national medical insurance negotiation[J]. Strait Pharmaceutical Journal, 2023, 35(4): 62-66.] DOI: 10.3969/j.issn.1006-3765.2023.04.019.

17.孙彦顺, 王陵, 姜诗瑶, 等. 基于真实世界的肿瘤免疫治疗药物PD-1/PD-L1抑制剂使用情况分析[J]. 中国医科大学学报, 2023, 52(9): 769-774. [Sun YS, Wang L, Jiang SY, et al. Use of programmed death-1/programmed death-ligand 1 inhibitors based on the real world[J]. Journal of China Medical University, 2023, 52(9): 769-774.] DOI: 10.12007/j.issn.0258-4646.2023.09.001.